Guideline Recommendations for 6 mm Lower Pole Renal Stones

Initial Management Decision

• Active surveillance is an acceptable strategy for asymptomatic, non‑obstructing lower‑pole stones up to 15 mm, provided that mandatory follow‑up imaging is performed (European Association of Urology guideline) 3
• Surgical intervention is indicated when the patient is symptomatic, the stone shows growth, there is an associated infection, or occupational factors require prompt treatment 2, 3

Indications for Intervention

• For lower‑pole stones smaller than 10 mm, the primary treatment options are flexible ureteroscopy (fURS) or shock‑wave lithotripsy (SWL) 1, 2, 3

Treatment Selection

Flexible Ureteroscopy (fURS) – Preferred First‑Line Option

• fURS and SWL are both first‑line options for a 6 mm lower‑pole stone, but fURS is generally preferred because it yields higher stone‑free rates 1, 2, 3

Shock‑Wave Lithotripsy (SWL) – Acceptable Alternative

• SWL may be chosen when the patient prefers a less invasive approach and values quality‑of‑life outcomes 4
• SWL is suitable when stone characteristics are favorable (low density, short skin‑to‑stone distance, and favorable collecting‑system anatomy) 4
• SWL is an option when the patient has contraindications to endoscopic procedures 4

Post‑SWL Adjunct

• Alpha‑blockers should be prescribed after SWL to facilitate passage of residual fragments 1, 3

Percutaneous Nephrolithotomy (PCNL) – Not Indicated

• PCNL should not be offered for a 6 mm lower‑pole stone 1, 2, 3
• PCNL is reserved for lower‑pole stones measuring 10–20 mm or larger 1, 2, 3

Pre‑Treatment Evaluation

• Obtain urine microscopy and culture to exclude or treat urinary‑tract infection before stone removal 5
• Perform stone analysis for all first‑time stone formers 5
• Use low‑dose CT to obtain accurate stone size and assess collecting‑system anatomy 5

Anatomical Factors Influencing Success

• An acute infundibulopelvic angle reduces SWL success rates 6
• A narrow infundibular width also diminishes SWL efficacy 1
• These unfavorable anatomical features have less impact on fURS outcomes (no citation needed)

Anticoagulation and Bleeding Risk

• When continuous anticoagulation or antiplatelet therapy cannot be interrupted, fURS is strongly recommended as the first‑line therapy 7, 8, 9
• fURS can be safely performed in patients with bleeding diatheses, unlike SWL and PCNL 7, 8

Peri‑ and Post‑Procedural Management

• Administer peri‑operative antibiotic prophylaxis before any endourological treatment 5
• A single prophylactic antibiotic dose before ureteroscopy is sufficient 5
• Routine ureteral stent placement is not recommended after the procedure unless specific indications exist 2
• If a stent is placed, prescribe alpha‑blockers or antimuscarinics to reduce stent‑related discomfort 2

Common Pitfalls and Contra‑Indications

• Do not select SWL as first‑line therapy when stone density exceeds 1000 HU or when the patient is obese with a large skin‑to‑stone distance 4
• If purulent urine is encountered during the procedure, abort the intervention, establish drainage, obtain a urine culture, and continue antibiotics 6, 7
• Avoid multiple failed SWL attempts; if the initial SWL session is unsuccessful, proceed to endoscopic therapy (fURS) as the next treatment 6, 7